Senators question Allergan CEO on tribe patent deal
Por um escritor misterioso
Descrição
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology
A handful of Allergan's top shareholders want to bring back the old CEO as chairman
Senators blast Allergan's tribal deal, social contract as 'hypocrisy
A handful of Allergan's top shareholders want to bring back the old CEO as chairman
Speaker Bios Do Not Delete - Foundry Events
Allergan settles Restasis litigation with Pfizer's InnoPharma as backlash mounts over tribal patent deal
CIPA Journal, November 2017 by CIPA Journal - Issuu
Allergan Patent Deal May Hurt Competition, Lawmakers Say - Bloomberg
Allergan does patent deal for Restasis with Native American tribe
By Any Means Necessary - Public Citizen
Supreme Court's Arthrex decision creates more review for patent owners — and more questions - Medical Design and Outsourcing
de
por adulto (o preço varia de acordo com o tamanho do grupo)
